B · Normal
[Biotech: Udrome® received drug registration certificate] On October 22, Biotel (688177.SH) announced that the company had received the "Drug Registration Certificate" for Secukinumab Injection (trade name: Udrome®) approved and issued by the State Food and Drug Administration. The approved indications are psoriasis, ankylosing spondylitis, and psoriatic arthritis. The drug is the world's first biosimilar to secukinumab. The original drug Cosentyx® will have global net sales of US$6.668 billion in 2025. Commercial authorization has covered 66 countries and regions around the world.
Comments